Rituximab restored the muscle power and rescued from a refractory fatal respiratory failure in a patient with elderly-onset polymyositis

Joint Bone Spine

Volumn 79, Issue 1, 2012, Pages 101-102

  Gheita, Tamer A ^a   Gheita, Heba A ^b   Kenawy, Sanaa A ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b HOT LABORATORIES CENTER   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Elderly onset polymyositis; Respiratory failure; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ANTIBIOTIC THERAPY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DISEASE EXACERBATION; ELECTROMYOGRAM; FATIGUE; FEMALE; GERIATRIC PATIENT; HUMAN; LETTER; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; ONSET AGE; PLEURA EFFUSION; POLYMYOSITIS; REMISSION; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RETREATMENT; STEROID THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CREATINE KINASE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MUSCLE STRENGTH; POLYMYOSITIS; RECOVERY OF FUNCTION; REMISSION INDUCTION; RESPIRATORY INSUFFICIENCY;

EID: 84855709532     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.06.006     Document Type: Letter

References (10)

1. Tournadre A., Dubost J.J., Soubrier M. Treatment of inflammatory muscle disease in adults. Joint Bone Spine 2010, 77:390-394.
2. Levesque M.C. Translational mini-review series on b cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009, 157:198-208.
3. Rios Fernández R., Callejas Rubio J.L., Sánchez Cano D., et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009, 27:1009-1016.
4. Dalakas M.C. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010, 6:129-137.
5. Chakour R., Leimgruber A., Bart P.A., et al. Therapeutic strategies in idiopathic inflammatory myopathies. Rev Med Suisse 2009, 5:812-818.
6. Hengstman G.J., van den Hoogen F.H., van Engelen B.G. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009, 10:1183-1190.
7. Tanimoto K., Nakano K., Kano S., et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995, 22:668-674.
8. Lee M.A., Hutchinson D.G. Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab. Clin Rheumatol 2010, 29:945-946.
9. Feist E., Dörner T., Sörensen H., et al. Long lasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008, 35:1230-1232.
10. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.